Express Pharma

Boehringer Ingelheim launches additional heart failure indication for Jardiance in India

Empagliflozin - the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death, in people with type-II diabetes and established cardiovascular disease, is now evidenced for heart failure with preserved as well as reduced ejection fraction